中国组织工程研究 ›› 2021, Vol. 25 ›› Issue (7): 1096-1103.doi: 10.3969/j.issn.2095-4344.2126
• 干细胞综述 stem cell review • 上一篇 下一篇
廖成成1,安家兴2,谭张雪1,王 倩3,刘建国1,3
收稿日期:
2020-02-17
修回日期:
2020-02-25
接受日期:
2020-03-20
出版日期:
2021-03-08
发布日期:
2020-12-09
通讯作者:
王倩,博士,副教授,贵州省高等学校口腔疾病研究特色重点实验室,贵州省遵义市 563000
刘建国,博士,教授,遵义医科大学口腔医学院,贵州省遵义市 563000;贵州省高等学校口腔疾病研究特色重点实验室,贵州省遵义市 563000
作者简介:
廖成成,男,1995年生,浙江省江山市人,汉族,遵义医科大学在读硕士,主要从事头颈部鳞状细胞癌的研究。
基金资助:
Liao Chengcheng1, An Jiaxing2, Tan Zhangxue1, Wang Qian3, Liu Jianguo1, 3
Received:
2020-02-17
Revised:
2020-02-25
Accepted:
2020-03-20
Online:
2021-03-08
Published:
2020-12-09
Contact:
Wang Qian, MD, Associate professor, Special Key Laboratory of Oral Disease Research, Higher Education Institution in Guizhou Province, Zunyi 563000, Guizhou Province, China
Liu Jianguo, MD, Professor, School of Stomatology, Zunyi Medical University, Zunyi 563000, Guizhou Province, China; Special Key Laboratory of Oral Disease Research, Higher Education Institution in Guizhou Province, Zunyi 563000, Guizhou Province, China
About author:
Liao Chengcheng, Master candidate, School of Stomatology, Zunyi Medical University, Zunyi 563000, Guizhou Province, China
Supported by:
摘要:
文题释义:
口腔鳞状细胞癌:是最常见的口腔肿瘤,吸烟、饮酒和咀嚼槟榔是导致其发病的常见危险因素。在中国湖南等省份发病率较高,多见于40-60岁的成年男性,手术是其主要治疗方法。口腔鳞状细胞癌常常向区域淋巴结转移,晚期可发生远处转移,患者5年生存率较低。
肿瘤干细胞:是肿瘤细胞中数量较少的一类细胞,具有自我更新和分化为不同类型肿瘤细胞的能力。肿瘤干细胞对肿瘤的存活、增殖、转移及复发有着重要作用。从本质上讲,肿瘤干细胞通过自我更新和无限增殖维持着肿瘤细胞群的生命力。因此靶向干预肿瘤干细胞是治疗肿瘤的有效方法,也是目前肿瘤干细胞研究的热点之一。
背景:肿瘤干细胞是肿瘤细胞中数量较少的一类细胞,具有自我更新和分化为不同类型肿瘤细胞的能力。口腔鳞状细胞癌干细胞具有高度的致瘤性,并在肿瘤分化、治疗抵抗、复发和转移中发挥作用,同时肿瘤干细胞与正常干细胞具有极大的相似性,因此有必要建立有效、准确的肿瘤干细胞鉴定方法,设计对应的靶向治疗策略,这有助于口腔鳞状细胞癌患者的预后。
目的:总结目前文献中用于鉴定、分离口腔鳞状细胞癌干细胞的方法,分析针对口腔鳞状细胞癌干细胞进行治疗的潜在靶点,并总结这些潜在靶点的研究进展。
方法:运用计算机检索中国期刊全文数据库和PubMed数据库,纳入建库以来至2020年发表的相关文献。检索英文关键词为“oral squamous cell carcinoma,OSCC,cancer stem cells,HNSCC,head and neck squamous carcinoma cell”,中文检索词为“口腔鳞状细胞癌干细胞,口腔鳞状细胞癌,肿瘤干细胞,头颈部鳞状细胞癌”。对检索结果进行系统的归纳、总结和分析,并排除相关性低、重复文献和陈旧文献。
结果与结论:靶向干预口腔鳞状细胞癌干细胞具有重要的临床意义。CD44、CD133和ALDH是目前最合适的鉴别、分离口腔鳞状细胞癌干细胞的生物标记物,与Oct3/4、Nanog、Sox2、Bmi1、EGFR信号通路、SHH信号通路、Notch信号通路、Wnt信号通路、Let-7家族、MicroRNA-200家族和天然化合物一起作为靶向治疗口腔鳞状细胞癌的潜在靶点。
中图分类号:
廖成成, 安家兴, 谭张雪, 王 倩, 刘建国. 口腔鳞状细胞癌干细胞的治疗靶点及应用前景[J]. 中国组织工程研究, 2021, 25(7): 1096-1103.
Liao Chengcheng, An Jiaxing, Tan Zhangxue, Wang Qian, Liu Jianguo. Therapeutic target and application prospects of oral squamous cell carcinoma stem cells[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(7): 1096-1103.
[1] ZHONG LP, ZHANG CP, REN GX, et al. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. Oncotarget. 2015;6(21):18707-18714. [2] LIAN Q, MA DM, CHEN MG, et al. Silencing Rab14 represses the proliferation and migration of oral squamous cell carcinoma, and enhances cisplatin sensitivity. Am J Transl Res. 2017;9(9): 4195-4205. [3] COSTEA DE, TSINKALOVSKY O, VINTERMYR OK, et al. Cancer stem cells - new and potentially important targets for the therapy of oral squamous cell carcinoma. Oral Dis. 2006;12(5): 443-454. [4] BIANCHINI C, CIORBA A, STOMEO F, et al. Immunonutrition in head and neck cancer: have a look before surgery! Eur Arch Otorhinolaryngol. 2012;269(1):5-8. [5] DIANAT-MOGHADAM H, HEIDARIFARD M, JAHANBAN-ESFAHLAN R, et al. Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems. J Control Release. 2018;288:62-83. [6] TABOR MH, CLAY MR, OWEN JH, et al. Head and neck cancer stem cells: the side population. Laryngoscope. 2011;121(3): 527-533. [7] STRANSKY N, EGLOFF AM, TWARD AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333(6046):1157-1160. [8] PRINCE ME, SIVANANDAN R, KACZOROWSKI A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007; 104(3):973-978. [9] PRINCE ME, AILLES LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol. 2008;26(17):2871-2875. [10] SATPUTE PS, HAZAREY V, AHMED R, et al. Cancer stem cells in head and neck squamous cell carcinoma: a review. Asian Pac J Cancer Prev. 2013;14(10):5579-5587. [11] ZHANG Q, SHI S, YEN Y, et al. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett. 2010; 289(2):151-160. [12] MAJOR AG, PITTY LP, FARAH CS. Cancer stem cell markers in head and neck squamous cell carcinoma. Stem Cells Int. 2013; 2013:319489. [13] CHEN D, WANG CY. Targeting cancer stem cells in squamous cell carcinoma. Precis Clin Med. 2019;2(3):152-165. [14] KIM H, KIM M, IM SK, et al. Mouse Cre-LoxP system: general principles to determine tissue-specific roles of target genes. Lab Anim Res. 2018; 34(4):147-159. [15] CHEN D, WU M, LI Y, et al. Targeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma. Cell Stem Cell. 2017;20(5):621-634. [16] OSHIMORI N, ORISTIAN D, FUCHS E. TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell. 2015;160(5): 963-976. [17] PRASAD S, RAMACHANDRAN S, GUPTA N, et al. Cancer cells stemness: A doorstep to targeted therapy. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165424. [18] SCHEPERS AG, SNIPPERT HJ, STANGE DE, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science. 2012; 337(6095):730-735. [19] MISHRA MN, CHANDAVARKAR V, SHARMA R, et al. Structure, function and role of CD44 in neoplasia. J Oral Maxillofac Pathol. 2019;23(2): 267-272. [20] MONTEIRO LS, DELGADO ML, RICARDO S, et al. Prognostic significance of CD44v6, p63, podoplanin and MMP-9 in oral squamous cell carcinomas. Oral Dis. 2016;22(4):303-312. [21] MĂRGĂRITESCU C, PIRICI D, SIMIONESCU C, et al. The utility of CD44, CD117 and CD133 in identification of cancer stem cells (CSC) in oral squamous cell carcinomas (OSCC). Rom J Morphol Embryol. 2011; 52(3 Suppl):985-993. [22] MISHRA A, VERMA M. Cancer biomarkers: are we ready for the prime time? Cancers (Basel). 2010;2(1):190-208. [23] KAROUSOU E, MISRA S, GHATAK S, et al. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer. Matrix Biol. 2017;59:3-22. [24] SHERIDAN C, KISHIMOTO H, FUCHS RK, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res.2006;8(5): R59. [25] KASHYAP T, PRAMANIK KK, NATH N, et al. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer. Oral Oncol. 2018;86:234-243. [26] MORAND GB, IKENBERG K, VITAL DG, et al. Preoperative assessment of CD44-mediated depth of invasion as predictor of occult metastases in early oral squamous cell carcinoma. Head Neck. 2019;41(4):950-958. [27] SEYEDMAJIDI S, SEYEDMAJIDI M, FOROUGHI R, et al. Comparison of Salivary and Serum Soluble CD44 Levels between Patients with Oral SCC and Healthy Controls. Asian Pac J Cancer Prev. 2018;19(11): 3059-3063. [28] SOBREIRA TJ, MARLÉTAZ F, SIMÕES-COSTA M, et al. Structural shifts of aldehyde dehydrogenase enzymes were instrumental for the early evolution of retinoid-dependent axial patterning in metazoans. Proc Natl Acad Sci U S A. 2011;108(1): 226-231. [29] MADJD Z, RAMEZANI B, MOLANAE S, et al. High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev. 2012;13(6): 2973-2978. [30] NOZAKI Y, TAMORI S, INADA M, et al. Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer. Genes Cancer. 2017; 8(7-8):628-639. [31] JAYASOORIYA P, FERNANDO C, SURAWEERA A, et al. Stem cell markers as a resource to predict prognosis of betel quid induced oral squamous cell carcinoma: an immunohistochemical investigation. Stomatological Dis Sci 2017;1:29-34. [32] CANCER GENOME ATLAS NETWORK. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576-582. [33] KRISHNAMURTHY S, NÖR JE. Head and neck cancer stem cells. J Dent Res. 2012;91(4):334-340. [34] DINAVAHI SS, BAZEWICZ CG, GOWDA R, et al. Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics. Trends Pharmacol Sci. 2019;40(10): 774-789. [35] CHEN YC, CHEN YW, HSU HS, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009;385(3):307-313. [36] BARZEGAR BEHROOZ A, SYAHIR A, AHMAD S. CD133: beyond a cancer stem cell biomarker. J Drug Target. 2019;27(3):257-269. [37] HARPER LJ, PIPER K, COMMON J, et al. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med. 2007;36(10):594-603. [38] FUJII K, KUMAGAI K, HAMADA Y, et al. Clinicopathological significance and prognostic value of CD133 expression in oral squamous cell carcinoma. J Oral Maxillofac Surg Med Pathol. 2015;27(2):176-182. [39] YU CC, HU FW, YU CH, et al. Targeting CD133 in the enhancement of chemosensitivity in oral squamous cell carcinoma-derived side population cancer stem cells. Head Neck. 2016;38 Suppl 1:E231-238. [40] MOON Y, KIM D, SOHN H, et al. Effect of CD133 overexpression on the epithelial-to-mesenchymal transition in oral cancer cell lines. Clin Exp Metastasis. 2016;33(5):487-496. [41] SUN Y, HAN J, LU Y, et al. Biological characteristics of a cell subpopulation in tongue squamous cell carcinoma. Oral Dis. 2012; 18(2):169-177. [42] CAI J, HE B, LI X, et al. Regulation of tumorigenesis in oral epithelial cells by defined reprogramming factors Oct4 and Sox2. Oncol Rep. 2016; 36(2):651-658. [43] CHIOU SH, YU CC, HUANG CY, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2008;14(13): 4085-4095. [44] REYA T, MORRISON SJ, CLARKE MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111. [45] SHEN G, SHEN F, SHI Z, et al. Identification of cancer stem-like cells in the C6 glioma cell line and the limitation of current identification methods. In Vitro Cell Dev Biol Anim. 2008;44(7): 280-289. [46] QIAO B, HE B, CAI J, et al. The expression profile of Oct4 and Sox2 in the carcinogenesis of oral mucosa. Int J Clin Exp Pathol. 2013; 7(1):28-37. [47] HABU N, IMANISHI Y, KAMEYAMA K, et al. Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma. BMC Cancer. 2015;15:730. [48] HUANG CF, XU XR, WU TF, et al. Correlation of ALDH1, CD44, OCT4 and SOX2 in tongue squamous cell carcinoma and their association with disease progression and prognosis. J Oral Pathol Med. 2014;43(7): 492-498. [49] XIE X, PIAO L, CAVEY GS, et al. Phosphorylation of Nanog is essential to regulate Bmi1 and promote tumorigenesis. Oncogene. 2014; 33(16): 2040-2052. [50] WATANABE M, OHNISHI Y, INOUE H, et al. NANOG expression correlates with differentiation, metastasis and resistance to preoperative adjuvant therapy in oral squamous cell carcinoma. Oncol Lett. 2014;7(1):35-40. [51] SEINO S, SHIGEISHI H, HASHIKATA M, et al. CD44(high)/ ALDH1(high) head and neck squamous cell carcinoma cells exhibit mesenchymal characteristics and GSK3β-dependent cancer stem cell properties. J Oral Pathol Med. 2016;45(3): 180-188. [52] DALERBA P, CHO RW, CLARKE MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267-284. [53] SAITO S, ONUMA Y, ITO Y, et al. Possible linkages between the inner and outer cellular states of human induced pluripotent stem cells. BMC Syst Biol. 2011;5 Suppl 1:S17. [54] DE VICENTE JC, DONATE-PÉREZ DEL MOLINO P, RODRIGO JP, et al. SOX2 Expression Is an Independent Predictor of Oral Cancer Progression. J Clin Med. 2019;8(10). pii: E1744. [55] LEE SH, OH SY, DO SI, et al. SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma. Br J Cancer. 2014;111(11):2122-2130. [56] TAN YS, SANSANAPHONGPRICHA K, XIE Y, et al. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. Clin Cancer Res. 2018;24(17):4242-4255. [57] KEYSAR SB, LE PN, MILLER B, et al. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. J Natl Cancer Inst. 2016;109(1):djw189. [58] SCHRÖCK A, BODE M, GÖKE FJ, et al. Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma. Carcinogenesis. 2014;35(7):1636-1642. [59] CHEN YC, CHANG CJ, HSU HS, et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol. 2010;46(3):158-165. [60] HÄYRY V, MÄKINEN LK, ATULA T, et al. Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br J Cancer. 2010; 102(5):892-897. [61] HE Q, LIU Z, ZHAO T, et al. Bmi1 drives stem-like properties and is associated with migration, invasion, and poor prognosis in tongue squamous cell carcinoma. Int J Biol Sci. 2015;11(1):1-10. [62] NÖR C, ZHANG Z, WARNER KA, et al. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer. Neoplasia. 2014;16(2):137-146. [63] KASEB HO, FOHRER-TING H, LEWIS DW, et al. Identification, expansion and characterization of cancer cells with stem cell properties from head and neck squamous cell carcinomas. Exp Cell Res. 2016;348(1):75-86. [64] WANG Q, LI Z, WU Y, et al. Pharmacological inhibition of Bmi1 by PTC-209 impaired tumor growth in head neck squamous cell carcinoma. Cancer Cell Int. 2017;17:107. [65] MILLA LA, GONZÁLEZ-RAMÍREZ CN, PALMA V. Sonic Hedgehog in cancer stem cells: a novel link with autophagy. Biol Res. 2012;45(3): 223-230. [66] TICKLE C, TOWERS M. Sonic Hedgehog Signaling in Limb Development. Front Cell Dev Biol. 2017;5:14. [67] XU Q, YUAN X, LIU G, et al. Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas. Stem Cells. 2008;26(12): 3018-3026. [68] ZHOU M, HOU Y, YANG G, et al. LncRNA-Hh Strengthen Cancer Stem Cells Generation in Twist-Positive Breast Cancer via Activation of Hedgehog Signaling Pathway. Stem Cells. 2016; 34(1):55-66. [69] ZHANG C, LI C, HE F, et al. Identification of CD44+CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol. 2011;137(11): 1679-1686. [70] ZHANG K, CHE S, PAN C, et al. The SHH/Gli axis regulates CD90-mediated liver cancer stem cell function by activating the IL6/JAK2 pathway. J Cell Mol Med. 2018;22(7):3679-3690. [71] CAVICCHIOLI BUIM ME, GURGEL CA, GONÇALVES RAMOS EA, et al. Activation of sonic hedgehog signaling in oral squamous cell carcinomas: a preliminary study. Hum Pathol. 2011;42(10): 1484-1490. [72] FAN HX, WANG S, ZHAO H, et al. Sonic hedgehog signaling may promote invasion and metastasis of oral squamous cell carcinoma by activating MMP-9 and E-cadherin expression. Med Oncol.2014; 31(7): 41. [73] RODRIGUES MFSD, MIGUITA L, DE ANDRADE NP, et al. GLI3 knockdown decreases stemness, cell proliferation and invasion in oral squamous cell carcinoma. Int J Oncol. 2018;53(6):2458-2472. [74] NUSSE R, CLEVERS H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017;169(6):985-999. [75] CLEVERS H, LOH KM, NUSSE R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014;346(6205):1248012. [76] FELTHAUS O, ETTL T, GOSAU M, et al. Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell lines. Biochem Biophys Res Commun. 2011;407(1):28-33. [77] LIM YC, KANG HJ, KIM YS, et al. All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/β-catenin pathway. Eur J Cancer. 2012;48(17):3310-3318. [78] WARRIER S, BHUVANALAKSHMI G, ARFUSO F, et al. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gene Ther. 2014;21(9):381-388. [79] LE PN, KEYSAR SB, MILLER B, et al. Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions. Mol Carcinog. 2019;58(3):398-410. [80] WANG SJ, BOURGUIGNON LY. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006;132(7):771-778. [81] ARGIRIS A, HARRINGTON KJ, TAHARA M, et al. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Front Oncol. 2017;7:72. [82] TANG AL, HAUFF SJ, OWEN JH, et al. UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line. Head Neck. 2012;34(10):1480-1491. [83] PEREZ A, NESKEY DM, WEN J, et al. CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression. Oral Oncol. 2013;49(4):306-313. [84] CHATTERJEE S, SIL PC. Targeting the crosstalks of Wnt pathway with Hedgehog and Notch for cancer therapy. Pharmacol Res. 2019;142: 251-261. [85] MEURETTE O, MEHLEN P. Notch Signaling in the Tumor Microenvironment. Cancer Cell. 2018;34(4):536-548. [86] CHU Q, ORR BA, SEMENKOW S, et al. Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade. Clin Cancer Res. 2013;19(12):3224-3233. [87] PANNUTI A, FOREMAN K, RIZZO P, et al. Targeting Notch to target cancer stem cells. Clin Cancer Res. 2010;16(12): 3141-3152. [88] ZHAO ZL, ZHANG L, HUANG CF, et al. NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell. Sci Rep. 2016;6:24704. [89] AGRAWAL N, FREDERICK MJ, PICKERING CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333(6046): 1154-1157. [90] ROUSH S, SLACK FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008;18(10):505-516. [91] BALZEAU J, MENEZES MR, CAO S, et al. The LIN28/let-7 Pathway in Cancer. Front Genet. 2017;8:31. [92] CHIEN CS, WANG ML, CHU PY, et al. Lin28B/Let-7 Regulates Expression of Oct4 and Sox2 and Reprograms Oral Squamous Cell Carcinoma Cells to a Stem-like State. Cancer Res. 2015;75(12):2553-2565. [93] YU CC, CHEN YW, CHIOU GY, et al. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol. 2011;47(3):202-210. [94] PENG CY, WANG TY, LEE SS, et al. Let-7c restores radiosensitivity and chemosensitivity and impairs stemness in oral cancer cells through inhibiting interleukin-8. J Oral Pathol Med. 2018;47(6): 590-597. [95] CHANG CJ, HSU CC, CHANG CH, et al. Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol Rep. 2011;26(4): 1003-1010. [96] PARK SM, GAUR AB, LENGYEL E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008; 22(7): 894-907. [97] BRABLETZ S, BRABLETZ T. The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep. 2010;11(9):670-677. [98] ARUNKUMAR G, DEVA MAGENDHRA RAO AK, MANIKANDAN M, et al. Dysregulation of miR-200 family microRNAs and epithelial-mesenchymal transition markers in oral squamous cell carcinoma. Oncol Lett. 2018;15(1):649-657. [99] TAMAGAWA S, BEDER LB, HOTOMI M, et al. Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. Int J Mol Med. 2014;33(4):879-886. [100] LO WL, YU CC, CHIOU GY, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J Pathol. 2011;223(4): 482-495. [101] KIM T, VERONESE A, PICHIORRI F, et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med. 2011;208(5):875-883. [102] KU TK, NGUYEN DC, KARAMAN M, et al. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. Mol Cancer Res. 2007; 5(4):351-362. [103] TSAI CF, HSIEH TH, LEE JN, et al. Curcumin Suppresses Phthalate-Induced Metastasis and the Proportion of Cancer Stem Cell (CSC)-like Cells via the Inhibition of AhR/ERK/SK1 Signaling in Hepatocellular Carcinoma. J Agric Food Chem. 2015;63(48): 10388-10398. [104] SZTILLER-SIKORSKA M, KOPROWSKA K, MAJCHRZAK K, et al. Natural compounds’ activity against cancer stem-like or fast-cycling melanoma cells. PLoS One. 2014;9(3):e90783. [105] JIANG P, XU C, ZHOU M, et al. RXRα-enriched cancer stem cell-like properties triggered by CDDP in head and neck squamous cell carcinoma (HNSCC). Carcinogenesis. 2018; 39(2):252-262. [106] BAHARUDDIN P, SATAR N, FAKIRUDDIN KS, et al. Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines. Oncol Rep. 2016;35(1): 13-25. [107] CHAIB I, CAI X, LLIGE D, et al. Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma. Ann Transl Med. 2019;7(22):651. |
[1] | 林清凡, 解一新, 陈婉清, 叶振忠, 陈幼芳. 人胎盘源间充质干细胞条件培养液可上调缺氧状态下BeWo细胞活力和紧密连接因子的表达[J]. 中国组织工程研究, 2021, 25(在线): 4970-4975. |
[2] | 蒲 锐, 陈子扬, 袁凌燕. 不同细胞来源外泌体保护心脏的特点与效应[J]. 中国组织工程研究, 2021, 25(在线): 1-. |
[3] | 袁家威, 张海涛, 揭 珂, 曹厚然, 曾意荣. 基于网络药理学研究桃红四物汤治疗假体周围感染的潜在靶点和机制[J]. 中国组织工程研究, 2021, 25(9): 1428-1433. |
[4] | 张 超, 吕 欣. 髋臼骨折固定后的异位骨化:危险因素、预防及其治疗进展[J]. 中国组织工程研究, 2021, 25(9): 1434-1439. |
[5] | 周继辉, 李新志, 周 游, 黄 卫, 陈文瑶. 髌骨骨折修复内植物选择的多重问题[J]. 中国组织工程研究, 2021, 25(9): 1440-1445. |
[6] | 王德斌, 毕郑刚. 尺骨鹰嘴骨折-脱位解剖力学、损伤特点、固定修复及3D技术应用的相关问题[J]. 中国组织工程研究, 2021, 25(9): 1446-1451. |
[7] | 顾 霞, 赵 敏, 王平义, 李一梅, 李文华. 低氧诱导因子1α与低氧相关疾病信号通路的关系[J]. 中国组织工程研究, 2021, 25(8): 1284-1289. |
[8] | 姬志祥, 蓝常贡. 尿酸盐转运蛋白在痛风中的多态性和治疗相关性[J]. 中国组织工程研究, 2021, 25(8): 1290-1298. |
[9] | 袁 美, 张新新, 郭祎莎, 毕 霞. 循环microRNA在血管性认知障碍诊断中的应用[J]. 中国组织工程研究, 2021, 25(8): 1299-1304. |
[10] | 李嘉程, 梁学振, 刘金豹, 许 波, 李 刚. 骨性关节炎mRNA差异表达谱及竞争性内源RNA调控的网络分析[J]. 中国组织工程研究, 2021, 25(8): 1212-1217. |
[11] | 柴 乐, 吕建兰, 胡劲涛, 胡华辉, 许庆军, 余进伟, 全仁夫. 诱导急性脊髓损伤模型大鼠炎症反应信号通路的变化[J]. 中国组织工程研究, 2021, 25(8): 1218-1223. |
[12] | 耿秋东, 葛海雅, 王和鸣, 李 楠. 基于网络药理学探讨龟鹿二仙胶治疗骨关节炎的作用及机制[J]. 中国组织工程研究, 2021, 25(8): 1229-1236. |
[13] | 张秀梅, 翟运开, 赵 杰, 赵 萌. 类器官模型国内外数据库近10年文献研究热点分析[J]. 中国组织工程研究, 2021, 25(8): 1249-1255. |
[14] | 李中峰, 陈明海, 凡一诺, 魏秋实, 何 伟, 陈镇秋. 右归饮治疗激素性股骨头坏死作用机制的网络药理学分析[J]. 中国组织工程研究, 2021, 25(8): 1256-1263. |
[15] | 刘 聪, 刘 肃. miR-17-5p调控低氧诱导因子1α介导脂肪细胞分化及血管生成的分子机制[J]. 中国组织工程研究, 2021, 25(7): 1069-1074. |
文题释义:
口腔鳞状细胞癌:是最常见的口腔肿瘤,吸烟、饮酒和咀嚼槟榔是导致其发病的常见危险因素。在中国湖南等省份发病率较高,多见于40-60岁的成年男性,手术是其主要治疗方法。口腔鳞状细胞癌常常向区域淋巴结转移,晚期可发生远处转移,患者5年生存率较低。
肿瘤干细胞:是肿瘤细胞中数量较少的一类细胞,具有自我更新和分化为不同类型肿瘤细胞的能力。肿瘤干细胞对肿瘤的存活、增殖、转移及复发有着重要作用。从本质上讲,肿瘤干细胞通过自我更新和无限增殖维持着肿瘤细胞群的生命力。因此靶向干预肿瘤干细胞是治疗肿瘤的有效方法,也是目前肿瘤干细胞研究的热点之一。
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程肿瘤干细胞存在于肿瘤微环境中不同的解剖区域,这些小环境维持了肿瘤干细胞的基本特性,保持了它们的表型可塑性,保护它们不受免疫系统的影响,并促进了它们的转移潜能。肿瘤微环境中的关键成分作为治疗肿瘤干细胞的靶点具有广阔的前景。但是,目前以肿瘤微环境为切入点研究靶向治疗肿瘤干细胞的相关文献仍然较少,而这可能成为研究口腔鳞状细胞癌干细胞的下一个热点。
值得一提的是,癌症患者的免疫系统可能识别出肿瘤干细胞并杀死肿瘤干细胞,设计以免疫检查点为靶点的靶向治疗肿瘤干细胞策略是一个值得关注的领域,遗憾的是口腔鳞状细胞癌干细胞的相应研究仍未形成体系。不过研究者们仍然对口腔鳞状细胞癌干细胞与人体免疫的相关研究充满期待。
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||